cas 1628184-06-4|| where to buy 3-((2-Chloropyridin-4-yl)oxy)-6-iodo-2-methylpyridine

製品名:3-((2-Chloropyridin-4-yl)oxy)-6-iodo-2-methylpyridine

IUPAC Name:3-[(2-chloropyridin-4-yl)oxy]-6-iodo-2-methylpyridine

包装単位	有効在庫	価格（USD）
CM535948-100mg	in stock	ƛƿǶ
CM535948-250mg	in stock	ƿƛƥ
CM535948-1g	in stock	ȡƿƥ
CM535948-5g	1-2 Weeks	ƛƿǶŵ
CM535948-10g	1-2 Weeks	ƿƛƥȺ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1628184-06-4 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:1628184-06-4; 分子式:C11H8ClIN2O; 融点:-; SMILESコード:CC1=NC(I)=CC=C1OC2=CC(Cl)=NC=C2; 密度:

: カタログ番号:CM535948; 分子量:346.55; 沸点:; MDL番号:; 保管方法:Store at room temperature

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Vimseltinib; Vimseltinib (DCC-3014) is a potent and highly selective oral CSF1R kinase inhibitor that selectively and effectively inhibits CSF1R by utilizing the unique characteristics of the switch control region that regulates kinase conformational activation. The key phase 3 MOTION study conducted by vimseltinib in patients with giant cell tumor of the tendon sheath (TGCT) has shown positive results, and it is expected to submit a listing application to the FDA and the European Union next year.